Sanofi has announced major restructuring, which will involve about 400 job cuts in the U.S.
Paris’ Sanofi has announced major restructuring, which will involve about 400 job cuts in the U.S. However, Sanofi is not the only company feeling the pain in the insulin market. Eli Lilly and Novo Nordisk have also been hit, with Novo Nordisk cutting 1,000 positions in 2016 and Lilly cutting around 3,500 in 2017.
Here’s a roundup of these stories and other top career news from the past month.
- Sanofi to Eliminate 400 U.S. Jobs
- Teva’s Job Cuts Hit 208 Philadelphia Employees
- GlaxoSmithKline CEO Replaced 50 Top Managers, Lured Execs From Google, Novartis and Teva
- Novartis Steals New Oncology Head From Pfizer
- Ironshore Laid Off Staff, Quietly Closed Down After Christmas
Read More From Karl Thiel:
Get Ready for the M&A Explosion
